How big is Biotricity, Inc.?

As of Jun 18, Biotricity, Inc. has a market capitalization of 11.96 million, with net sales of 13.27 million and a net profit of -10.66 million over the last four quarters. The company has shareholder's funds of -29.98 million and total assets of 5.94 million as of Mar 24.

Market Cap: As of Jun 18, Biotricity, Inc. has a market capitalization of 11.96 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Biotricity, Inc. reported net sales of 13.27 million and a net profit of -10.66 million.<BR><BR>Balance Sheet Snapshot: As of the latest reporting period in Mar 24, the company has shareholder's funds of -29.98 million and total assets amounting to 5.94 million.

What does Biotricity, Inc. do?

Biotricity, Inc. is a micro-cap company in the Software Products industry, reporting net sales of $4 million and a net loss of $1 million as of December 2024. It has a market cap of $11.96 million and key metrics indicating a loss-making status with a return on equity of 34.59%.

Overview: <BR>Biotricity, Inc. operates in the Software Products industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 11.96 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.82 <BR>Return on Equity: 34.59% <BR>Price to Book: -0.40<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Biotricity, Inc.?

Is Biotricity, Inc. overvalued or undervalued?

As of February 14, 2020, Biotricity, Inc. is considered a risky investment due to its overvaluation and significant financial distress, reflected in negative valuation metrics and a volatile stock performance, despite a recent year-to-date return of 114.87%.

As of 14 February 2020, the valuation grade for Biotricity, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued, as evidenced by a Price to Book Value of -0.44 and an EV to EBITDA ratio of -8.26, both of which suggest significant financial distress. Additionally, the company's P/E ratio is not applicable due to it being loss-making, further complicating its valuation.<BR><BR>In comparison to its peers, Biotricity's valuation metrics are concerning; for instance, CareCloud, Inc. has a P/E of 12.655, while Biotricity's is -3.7032, highlighting a stark contrast in financial health. Other risky peers like Intellinetics, Inc. and Zenvia, Inc. also show negative valuations, with EV to EBITDA ratios of -49.2573 and 4.5867, respectively. Notably, Biotricity's recent stock performance has been volatile, with a YTD return of 114.87% compared to the S&P 500's 12.22%, yet this is overshadowed by a 3Y return of -90.97%, indicating long-term challenges.

Is Biotricity, Inc. technically bullish or bearish?

As of September 2, 2025, Biotricity, Inc. shows a bullish trend with a year-to-date return of 114.87%, significantly outperforming the S&P 500, despite mixed signals from some technical indicators and long-term underperformance.

As of 2 September 2025, the technical trend for Biotricity, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average. The KST is also bullish on a weekly basis, while the monthly indicators show a mildly bullish stance. However, the RSI shows no signal on both weekly and monthly time frames. The Bollinger Bands indicate a mildly bullish trend weekly but are sideways monthly. Overall, the Dow Theory shows no trend weekly and mildly bullish monthly.<BR><BR>In terms of performance, Biotricity has a year-to-date return of 114.87%, significantly outperforming the S&P 500's 12.22% during the same period. However, over longer periods, the stock has underperformed, with a 3-year return of -90.97% compared to the S&P 500's 70.41%. <BR><BR>The current stance is bullish, with moderate strength indicated by the weekly MACD and moving averages, despite some mixed signals from other indicators.